[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610040":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":99,"collaborators":11,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":11,"eligibilityCriteria":107,"healthyVolunteers":103,"sex":108,"minAge":109,"maxAge":11,"enrollmentInfo":110,"targetDuration":11,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"Fisher and Paykel Healthcare","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Airvo 3 (with OptiO2) OptiO2 mode on","EXPERIMENTAL",null,[13],"Device: Closed loop oxygen control",{"label":15,"type":16,"description":11,"interventionNames":17},"Airvo 3 (with OptiO2) OptiO2 mode off","ACTIVE_COMPARATOR",[18],"Device: Manual titration",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DEVICE","Closed loop oxygen control","Nasal high flow with closed loop oxygen control",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Manual titration","Nasal high flow with manual titration",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Jenny Han","CONTACT","64 9 574 0123","optio2trial@fphcare.com",[36,55,70,84],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"The University of Alabama at Birmingham","RECRUITING","Birmingham","Alabama","35294","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-86.80249,33.52066,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":53,"phoneExt":11,"email":54},"Raymond C Wade","205-934-2490","rcwade@uab.edu",{"facility":56,"status":38,"city":57,"state":58,"zip":59,"country":42,"countryCode":43,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Central Iowa Hospital Corp - UnityPoint Health","Des Moines","Iowa","50309",{"type":45,"coordinates":61},[62,63],-93.60911,41.60054,{"lat":63,"lon":62},[66],{"name":67,"role":32,"phone":68,"phoneExt":11,"email":69},"Matthew Trump","515-205-4013","mtrump@iowaclinic.com",{"facility":71,"status":38,"city":72,"state":72,"zip":73,"country":42,"countryCode":43,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Icahn School of Medicine at Mount Sinai","New York","10029",{"type":45,"coordinates":75},[76,77],-74.00597,40.71427,{"lat":77,"lon":76},[80],{"name":81,"role":32,"phone":82,"phoneExt":11,"email":83},"Kathryn Dubowski","212-420-2377","Kathryn.Dubowski@mountsinai.org",{"facility":85,"status":38,"city":86,"state":87,"zip":88,"country":42,"countryCode":43,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Temple University Hospital","Philadelphia","Pennsylvania","19140",{"type":45,"coordinates":90},[91,92],-75.16362,39.95238,{"lat":92,"lon":91},[95],{"name":96,"role":32,"phone":97,"phoneExt":11,"email":98},"Gerard Criner","215-707-8113","Gerard.Criner@tuhs.temple.edu",{"type":100,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610040","closed-loop-oxygen-control-in-chronic-obstructive-pulmonary-disease-copd-patients-treated-with-nasal-high-flow-in-the-hospital-100610040",false,"NCT07222410","Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital","Closed Loop Oxygen Control in COPD Patients Treated With Nasal High Flow in the Hospital","Inclusion Criteria:\n\n* Has cognitive ability to provide informed consent\n* Aged 22 years or older\n* Hospitalized with hypoxemia\u002Frespiratory distress\n* Diagnosis of COPD\n* Candidate for\u002Fcurrently prescribed nasal high flow (flow rate of at least 25 L\u002Fmin) with supplemental oxygen, as assessed by the investigator\n* Expected duration of oxygen and nasal high flow therapy \\>24 hours (not necessarily continuous)\n\nExclusion Criteria:\n\n* Receiving Non Invasive Ventilation (NIV) or indicated for NIV as per European Respiratory Society \u002FAmerican Thoracic Society guidelines\n* Hemodynamic instability (systolic blood pressure \\\u003C90mmHg or requirement for vasopressor or inotropic support)\n* Patient receiving end of life care\n* Nasal or facial conditions precluding use of nasal high flow\n* Pregnancy or breastfeeding\n* Cognitive impairment or impaired consciousness precluding informed consent\n* Unsuitable for adhesive finger pulse oximetry, as assessed by the investigator\n* Any other condition which, at the investigator's discretion, is believed to present a safety risk to the patient if included\n* The presence of any active comorbidities that affect the patient's condition importantly in the next 30 days, as assessed by the investigator\n* Has already participated in this clinical trial","ALL","22 Years",{"count":111,"type":112},70,"ESTIMATED","INTERVENTIONAL",[115],"NA","The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia\u002Frespiratory distress.",[118],"COPD",[118,120,121,122],"closed loop oxygen control","hypoxemia","nasal high flow","2026-06-21",{"date":125,"type":126},"2026-06-23","ACTUAL",{"date":128,"type":126},"2026-01-07",{"date":130,"type":112},"2027-11",{"name":5,"class":6},4]